DUBLIN – Pieris Pharmaceuticals Inc., logged its first partnering deal in immuno-oncology, a pact worth up to CHF415 million (US$416 million) with Roche AG, involving a single undisclosed target against which the German-American biotech will deploy its anticalin scaffold technology.